Decoy Therapeutics Inc. (DCOY)
NASDAQ: DCOYHealthcareBiotechnologyUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
DCOY stock chart
Technical analysisKey statistics
All statistics- Market cap
- $995.88K
- P/E (TTM)
- 0.12
- EPS (TTM)
- $12.18
- Dividend yield
- None
- 52-week range
- 1.48 – 55.92
- Day range
- 1.48 – 1.62
- Volume / Avg
- 121.37K / 2.17M
- Beta
- —
- Shares outstanding
- 655.18K
52-week range
DCOY stock today
Decoy Therapeutics (DCOY) closed at $1.52 on Oct 8, down 5.59% (-$0.09), versus the S&P 500's 0.47% decline. Trading was light, with 121.37K shares changing hands, about 6% of the average daily volume. Shares are 97.3% below their 52-week high of $55.92 and 2.7% above the 52-week low of $1.48, near the bottom of the past year's range.
At 0.1x trailing earnings, Decoy Therapeutics trades above the peer-group median of 0.0x.
Summary generated from market data by MetaCap's automated system. Methodology
About Decoy Therapeutics
Company profileDecoy Therapeutics Inc. operates as a pre-clinical stage biotechnology company. It focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that leverages peptide coiled-coils chemistry and physics to design a-helical peptides through computational and ML tools.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Frederick E. Pierce II
- Headquarters
- Houston, TX
- Employees
- 11
- IPO year
- 2015
- Website
- decoytx.com
Analyst forecast
ForecastConsensus (1 analysts)
strong_buy
Avg. price target
$3.00+97.37%
- Strong buy 0
- Buy 1
- Hold 0
- Sell 0
- Strong sell 0
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Decoy Therapeutics peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| BDRXBiodexa Pharmaceuticals plc American Depositary Shs | 0.5237 | -7.11% | $1.15M | vs DCOY |
| BBLGBone Biologics Corp | 0.4691 | -3.77% | $1.29M | vs DCOY |
| SCNIScinai Immunotherapeutics Ltd. ADR | 1.21 | +7.08% | $1.64M | vs DCOY |
| CRISCuris Inc. | 0.7094 | -3.69% | $1.72M | vs DCOY |
| EDVAEndovia Health Sciences Inc. | 0.1599 | -3.09% | $1.77M | vs DCOY |
| ARTLArtelo Biosciences Inc. | 3.37 | -1.17% | $1.85M | vs DCOY |
| LABTLakewood-Amedex Biotherapeutics Inc. | 0.792 | -6.80% | $1.88M | vs DCOY |
| CDTCDT Equity Inc. | 0.80 | -4.31% | $32.43K | vs DCOY |
Indexes, lists and sector
Appears in lists
Decoy Therapeutics stock FAQ
What is Decoy Therapeutics's stock price today?
DCOY last traded at $1.52 as of Oct 8, 4:00 PM EDT, down 5.59% on the day. Prices are delayed at least 15 minutes.
What is DCOY's P/E ratio?
DCOY trades at a trailing P/E ratio of 0.12, compared with a median of 0.0 for its closest peers.
Who is Decoy Therapeutics's CEO?
Mr. Frederick E. Pierce II is the chief executive officer of Decoy Therapeutics Inc., which has about 11 employees.
What is the DCOY 52-week high?
The 52-week high for DCOY is $55.92 and the 52-week low is $1.48. The stock is currently 97.3% below its high.